Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Genomic Biomarkers

Ben Park's Biography



Ben Park, Associate Professor, Johns Hopkins University

Dr. Park is from Saginaw, MI and received his Bachelor’s degree from The University of Chicago in 1989. He then completed a dual M.D.-Ph.D. training program at The University of Pennsylvania School of Medicine graduating in 1995. After completing a residency in Internal Medicine and Hematology/Oncology Fellowship Training at The Hospital of The University of Pennsylvania, he finished a postdoctoral research fellowship in cancer genetics in the laboratory of Dr. Bert Vogelstein at Johns Hopkins University. In 2002, Dr. Park joined the Faculty in the Department of Oncology at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins within the Breast Cancer Program. Currently he is an Associate Professor of Oncology and Associate Director of the Medical Oncology Fellowship Program. His laboratory research focuses on finding mutated or altered genes that are responsible for breast cancer initiation and progression, as well as genes that are mutated leading to chemo- and hormonal drug resistance. Currently a new area of research is to exploit these discoveries to develop personalized DNA cancer biomarkers to guide individualized treatments for patients with breast cancer.

Ben Park Image

Plasma Tumor DNA Biomarkers: Applications and Implications for Breast Cancer Therapy

Thursday, 19 April 2012 at 11:45

Add to Calendar ▼2012-04-19 11:45:002012-04-19 12:45:00Europe/LondonPlasma Tumor DNA Biomarkers: Applications and Implications for Breast Cancer TherapySELECTBIOenquiries@selectbiosciences.com

The identification of somatic genomic alterations present in a patient’s breast cancer allows for the development of DNA biomarkers that are unique for every individual’s tumor. We can assess these DNA biomarkers in the plasma of breast cancer patients by quantitative PCR. This allows us to determine whether the presence or absence of plasma tumor DNA correlates with disease burden, response to therapy and ultimately clinical benefit for the patient.


Add to Calendar ▼2012-04-19 00:00:002012-04-20 00:00:00Europe/LondonGenomic BiomarkersSELECTBIOenquiries@selectbiosciences.com